Abstract
Objective To develop and validate a rapid scoring system at hospital admission for predicting in-hospital mortality in patients hospitalized with coronavirus disease 19 (COVID-19), and to compare this score with other existing ones.
Design Cohort study
Setting The Brazilian COVID-19 Registry has been conducted in 36 Brazilian hospitals in 17 cities. Logistic regression analysis was performed to develop a prediction model for in-hospital mortality, based on the 3978 patients that were admitted between March-July, 2020. The model was then validated in the 1054 patients admitted during August-September, as well as in an external cohort of 474 Spanish patients.
Participants Consecutive symptomatic patients (≥18 years old) with laboratory confirmed COVID-19 admitted to participating hospitals. Patients who were transferred between hospitals and in whom admission data from the first hospital or the last hospital were not available were excluded, as well those who were admitted for other reasons and developed COVID-19 symptoms during their stay.
Main outcome measures In-hospital mortality
Results Median (25th-75th percentile) age of the model-derivation cohort was 60 (48-72) years, 53.8% were men, in-hospital mortality was 20.3%. The validation cohorts had similar age distribution and in-hospital mortality. From 20 potential predictors, seven significant variables were included in the in-hospital mortality risk score: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO2/FiO2 ratio, platelet count and heart rate. The model had high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859) and Spanish (0.899) validation cohorts. Our ABC2-SPH score showed good calibration in both Brazilian cohorts, but, in the Spanish cohort, mortality was somewhat underestimated in patients with very high (>25%) risk. The ABC2-SPH score is implemented in a freely available online risk calculator (https://abc2sph.com/).
Conclusions We designed and validated an easy-to-use rapid scoring system based on characteristics of COVID-19 patients commonly available at hospital presentation, for early stratification for in-hospital mortality risk of patients with COVID-19.
Summary boxes What is already known on this topic?
Rapid scoring systems may be very useful for fast and effective assessment of COVID-19 patients in the emergency department.
The majority of available scores have high risk of bias and lack benefit to clinical decision making.
Derivation and validation studies in low- and middle-income countries, including Latin America, are scarce.
What this study adds
ABC2-SPH employs seven well defined variables, routinely assessed upon hospital presentation: age, number of comorbidities, blood urea nitrogen, C reactive protein, Spo2/FiO2 ratio, platelets and heart rate.
This easy-to-use risk score identified four categories at increasing risk of death with a high level of accuracy, and displayed better discrimination ability than other existing scores.
A free web-based calculator is available and may help healthcare practitioners to estimate the expected risk of mortality for patients at hospital presentation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by Minas Gerais State Agency for Research and Development (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais - FAPEMIG) [grant number APQ0020820] and National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliacao de Tecnologias em Saude IATS)/ National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq) [grant number 465518/20141]. AS was supported by a Postdoctoral grant Juan Rodes (JE18/00022) from Instituto de Salud Carlos III through the Ministry of Economy and Competitiveness, Spain.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol conforms to the ethical guidelines of the Declaration of Helsinki. It was approved by the Brazilian National Commission for Research Ethics (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the severity of the situation and the use of deidentified data based on medical chart review only. For the independent external validation cohort it was approved by the and Vall dHebron University Hospital Research Ethics Committee (PR(AG)183/2020). The institutional review board granted an informed consent waiver if patients were unable to give oral consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
milenamarc{at}ufmg.br, magda{at}est.ufmg.br, luckermos19{at}gmail.com, rafaelsilva{at}posteo.net, luanalmo19.09{at}gmail.com, rafaelsjdr{at}hotmail.com, rodolfo_use{at}hotmail.com, adrian.sanchez.montalva{at}gmail.com, berta.raventos{at}vhir.org, afernando{at}ghc.com.br, jmchatkin{at}pucrs.br, mathnogueira42{at}gmail.com, miltonhenriques{at}yahoo.com.br, ggvietta{at}gmail.com, hduani{at}yahoo.com.br, daniela.ponce{at}unesp.br, patriciakz99{at}gmail.com, pharmlucamsc{at}gmail.com, karenbruschel{at}gmail.com, christiane.cimini{at}gmail.com, saionaracf{at}gmail.com, maiara.floriani{at}hmv.org.br, guilhermefagundesn{at}hotmail.com, barbarafarace{at}gmail.com, luannasmonteiro{at}gmail.com, mairavsouza{at}gmail.com, thaislorennass30{at}yahoo.com.br, kkpmprado2{at}gmail.com, israeljbn{at}ufmg.br, tatianifereguetti{at}gmail.com, daniel{at}taiar.com.br, fbotoni{at}medicina.ufmg.br, anabsetges{at}gmail.com, h.boersma{at}erasmusmc.nl, carisi.anne{at}gmail.com
Data Availability
Data are available upon reasonable request.